Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Pancreatic Adenocarcinoma Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

9 recruiting trials for Pancreatic Adenocarcinoma. Eligibility criteria explained in plain English.

TrialFinderData lists 9 Pancreatic Adenocarcinoma clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 50% (4 studies); the largest phase groups are Phase 2: 4, Phase 1: 3, Phase 1 / Phase 2: 1.

Research is led by Clasp Therapeutics, Inc. (1), UNICANCER (1), Carol Davila University of Medicine and Pharmacy (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is CLSP-1025 (drug, 1 trial), followed by Dostarlimab, Chemotherapy.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
9
Total Trials
9
Recruiting Now
0
Phase 3 Trials
9
Sponsors

Track Pancreatic Adenocarcinoma trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1NCT06778863

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

Sponsor: Clasp Therapeutics, Inc.Enrolling: 9020 locations
RECRUITINGPhase 2NCT06333314

Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

The goal of this open-label randomized, multicenter, comparative phase II trial is to evaluate the efficacy of the immunotherapy, dostarlimab, as first-line treatment for...

Sponsor: UNICANCEREnrolling: 12020 locations
RECRUITINGNCT06867172

Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma

Several pancreatic neoplastic cystic lesions, such as IPMN (intrapapilary mucinous neoplasia), cystic neuroendocrine tumors (NET) and mucinous neoplasms, present a carcinogenetic...

Sponsor: Carol Davila University of Medicine and PharmacyEnrolling: 661 location
RECRUITINGPhase 1NCT04361708

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

The purpose of the proposed study is to establish the safety of combining irinotecan chemotherapy with 5-FU, leucovorin/folinic acid, oxaliplatin, and docetaxel (abbreviated as...

Sponsor: University of ChicagoEnrolling: 541 location
RECRUITINGPhase 2NCT06149689

mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer

The purpose of this study is to evaluate the efficacy of mFOLFIRINOX plus radiotherapy to Patients with CA19-9-normal Advanced Pancreatic Cancer.

Sponsor: Fudan UniversityEnrolling: 301 location
RECRUITINGPhase 2NCT06387342

Namodenoson Treatment of Advanced Pancreatic Cancer

This is an open-label trial in patients with advanced pancreatic cancer. The trial will evaluate the safety, clinical activity, and pharmacokinetics of the study drug,...

Sponsor: Can-Fite BioPharmaEnrolling: 201 location
RECRUITINGPhase 2NCT07126158

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

Advanced pancreatic cancer patients receiving treatment of adaptive stereotactic body radiotherapy (SBRT) with concurrent and adjuvant defactinib plus avutometinib will have...

Sponsor: Washington University School of MedicineEnrolling: 361 location
RECRUITINGPhase 1 / Phase 2NCT05000294

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this...

Sponsor: University of FloridaEnrolling: 291 location
RECRUITINGPhase 1NCT05245500

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid...

Sponsor: Bristol-Myers SquibbEnrolling: 33620 locations

Frequently Asked Questions

There are currently 9 clinical trials for Pancreatic Adenocarcinoma, with 9 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Pancreatic Adenocarcinoma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Pancreatic Adenocarcinoma, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.